1. McNeil, SE. Challenges for nanoparticle characterization. Methods Mol Biol 2011; 697: 9–15.
Google Scholar | Crossref | Medline2. McNeil, SE. Unique benefits of nanotechnology to drug delivery and diagnostics. Methods Mol Biol 2011; 697: 3–8.
Google Scholar | Crossref | Medline3. Caron, WP, Song, G, Kumar, P, et al. Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents. Clin Pharmacol Ther 2012; 91: 802–812.
Google Scholar | Crossref | Medline4. Prabhakar, U, Maeda, H, Jain, RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013; 73: 2412–2417.
Google Scholar | Crossref | Medline5. Zamboni, WC, Torchilin, V, Patri, AK, et al. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res 2012; 18: 3229–3241.
Google Scholar | Crossref | Medline | ISI6. Chauhan, VP, Stylianopoulos, T, Boucher, Y, et al. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2011; 2: 281–298.
Google Scholar | Crossref | Medline7. Jain, RK, Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010; 7: 653–664.
Google Scholar | Crossref | Medline | ISI8. Diop-Frimpong, B, Chauhan, VP, Krane, S, et al. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci USA 2011; 108: 2909–2914.
Google Scholar | Crossref | Medline | ISI9. Jain, RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013; 31: 2205–2218.
Google Scholar | Crossref | Medline | ISI10. Liu, J, Liao, S, Diop-Frimpong, B, et al. TGF-beta blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci USA 2012; 109: 16618–16623.
Google Scholar | Crossref | Medline11. Maeda, H, Nakamura, H, Fang, J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 2013; 65: 71–79.
Google Scholar | Crossref | Medline | ISI12. Raut, CP, Boucher, Y, Duda, DG, et al. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS ONE 2012; 7: e26331.
Google Scholar | Crossref13. Chu, KS, Hasan, W, Rawal, S, et al. Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. Nanomedicine 2013; 9: 686–693.
Google Scholar | Crossref | Medline14. Jain, RK, Munn, LL, Fukumura, D. Measuring vascular permeability in mice. Cold Spring Harb Protoc 2013; 2013: 444–446.
Google Scholar | Crossref | Medline15. Madden, AJ, Rawal, S, Sandison, K, et al. Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT). J Nanopart Res 2014; 16: 2662.
Google Scholar | Crossref | Medline16. Song, G, Darr, DB, Santos, CM, et al. Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. Clin Cancer Res 2014; 20: 6083–6095.
Google Scholar | Crossref | Medline17. Stylianopoulos, T, Martin, JD, Snuderl, M, et al. Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse. Cancer Res 2013; 73: 3833–3841.
Google Scholar | Crossref | Medline18. Walsh, MD, Hanna, SK, Sen, J, et al. Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts. Clin Cancer Res 2012; 18: 2591–2602.
Google Scholar | Crossref | Medline19. Zamboni, WC, Eiseman, JL, Strychor, S, et al. Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models. J Liposome Res 2011; 21: 70–80.
Google Scholar | Crossref | Medline20. Parrott, MC, Luft, JC, Byrne, JD, et al. Tunable bifunctional silyl ether cross-linkers for the design of acid-sensitive biomaterials. J Am Chem Soc 2010; 132: 17928–17932.
Google Scholar | Crossref | Medline21. Rolland, JP, Maynor, BW, Euliss, LE, et al. Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J Am Chem Soc 2005; 127: 10096–10100.
Google Scholar | Crossref | Medline22. Gabizon, A, Bradbury, M, Prabhakar, U, et al. Cancer nanomedicines: closing the translational gap. Lancet 2014; 384: 2175–2176.
Google Scholar | Crossref | Medline23. Tyldesley, S, Delaney, G, Foroudi, F, et al. Estimating the need for radiotherapy for patients with prostate, breast, and lung cancers: verification of model estimates of need with radiotherapy utilization data from British Columbia. Int J Radiat Oncol Biol Phys 2011; 79: 1507–1515.
Google Scholar | Crossref | Medline24. Fernandez-Palomo, C, Schultke, E, Brauer-Krisch, E, et al. Investigation of abscopal and bystander effects in immunocompromised mice after exposure to pencilbeam and microbeam synchrotron radiation. Health Phys 2016; 111: 149–159.
Google Scholar | Crossref | Medline25. Fontanella, AN, Boss, MK, Hadsell, M, et al. Effects of high-dose microbeam irradiation on tumor microvascular function and angiogenesis. Radiat Res 2015; 183: 147–158.
Google Scholar | Crossref | Medline | ISI26. Sedelnikova, OA, Nakamura, A, Kovalchuk, O, et al. DNA double-strand breaks form in bystander cells after microbeam irradiation of three-dimensional human tissue models. Cancer Res 2007; 67: 4295–4302.
Google Scholar | Crossref | Medline | ISI27. Brauer-Krisch, E, Serduc, R, Siegbahn, EA, et al. Effects of pulsed, spatially fractionated, microscopic synchrotron X-ray beams on normal and tumoral brain tissue. Mutat Res 2010; 704: 160–166.
Google Scholar | Crossref | Medline | ISI28. Griffin, RJ, Koonce, NA, Dings, RP, et al. Microbeam radiation therapy alters vascular architecture and tumor oxygenation and is enhanced by a galectin-1 targeted anti-angiogenic peptide. Radiat Res 2012; 177: 804–812.
Google Scholar | Crossref | Medline29. Griffin, R, Ahmed, MM, Amendola, BE, et al. Understanding high-dose, ultra-high dose-rate and spatially fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2020; 107: 766–778.
Google Scholar | Crossref | Medline30. Guardiola, C, Peucelle, C, Prezado, Y. Optimization of the mechanical collimation for minibeam generation in proton minibeam radiation therapy. Med Phys 2017; 44: 1470–1478.
Google Scholar | Crossref | Medline31. Fernandez-Palomo, C, Fazzari, J, Trappetti, V, et al. Animal models in microbeam radiation therapy: a scoping review. Cancers 2020; 12: 527.
Google Scholar | Crossref32. Choi, JI, Daniels, J, Cohen, D, et al. Clinical outcomes of spatially fractionated GRID radiotherapy in the treatment of bulky tumors of the head and neck. Cureus 2019; 11: e4637.
Google Scholar | Medline33. Mohiuddin, M, Fujita, M, Regine, WF, et al. High-dose spatially-fractionated radiation (GRID): a new paradigm in the management of advanced cancers. Int J Radiat Oncol Biol Phys 1999; 45: 721–727.
Google Scholar | Crossref | Medline | ISI34. Blanco Suarez, JM, Amendola, BE, Perez, N, et al. The use of lattice radiation therapy (LRT) in the treatment of bulky tumors: a case report of a large metastatic mixed mullerian ovarian tumor. Cureus 2015; 7: e389.
Google Scholar | Medline35. Mohiuddin, M, Lynch, C, Gao, M, et al. Early clinical results of proton spatially fractionated GRID radiation therapy (SFGRT). Br J Radiol 2020; 93: 20190572.
Google Scholar | Crossref | Medline36. Rivera, JN, Kierski, TM, Kasoji, SK, et al. Conventional dose rate spatially-fractionated radiation therapy (SFRT) treatment response and its association with dosimetric parameters—a preclinical study in a Fisher 344 rat model. PLoS ONE 2020; 15: e0229053.
Google Scholar | Crossref | Medline37. Fernandez-Palomo, C, Brauer-Krisch, E, Laissue, J, et al. Use of synchrotron medical microbeam irradiation to investigate radiation-induced bystander and abscopal effects in vivo. Phys Med 2015; 31: 584–595.
Google Scholar | Crossref | Medline38. Pfefferle, AD, Herschkowitz, JI, Usary, J, et al. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol 2013; 14: R125.
Google Scholar | Crossref | Medline39. Usary, J, Darr, DB, Pfefferle, AD, et al. Overview of genetically engineered mouse models of distinct breast cancer subtypes. Curr Protoc Pharmacol 2016; 72: 14.38.1–14.38.11.
Google Scholar | Crossref | Medline40. Herschkowitz, JI, Zhao, W, Zhang, M, et al. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci USA 2012; 109: 2778–2783.
Google Scholar | Crossref | Medline | ISI41. Merkel, TJ, Chen, K, Jones, SW, et al. The effect of particle size on the biodistribution of low-modulus hydrogel PRINT particles. J Control Release 2012; 162: 37–44.
Google Scholar | Crossref | Medline42. Song, G, Suzuki, OT, Santos, CM, et al. Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains. Nanomedicine 2016; 12: 2007–2017.
Google Scholar | Crossref | Medline43. Amselem, S, Gabizon, A, Barenholz, Y. Optimization and upscaling of doxorubicin-containing liposomes for clinical use. J Pharm Sci 1990; 79: 1045–1052.
Google Scholar | Crossref | Medline44. Anders, CK, Adamo, B, Karginova, O, et al. Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. PLoS ONE 2013; 8: e61359.
Google Scholar | Crossref45. Gabizon, A, Shiota, R, Papahadjopoulos, D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 1989; 81: 1484–1488.
Google Scholar | Crossref | Medline46. Petschauer, JS, Madden, AJ, Kirschbrown, WP, et al. The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents. Nanomedicine 2015; 10: 447–463.
Google Scholar | Crossref | Medline47. Zamboni, WC, Strychor, S, Joseph, E, et al. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Clin Cancer Res 2007; 13: 7217–7223.
Google Scholar | Crossref | Medline48. Budwit-Novotny, DA, McCarty, KS, Cox, EB, et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 1986; 46: 5419–5425.
Google Scholar